Strengthening Drug Product CMC through Drug Product Science | AAPS

As development programs accelerate, drug product CMC has emerged as a critical driver of risk, timelines, and regulatory confidence. Formulation design, stability behavior, and analytical control strategies increasingly shape comparability, lifecycle flexibility, and long‑term product robustness across dosage forms and therapeutic areas.

The AAPS Annual Meeting brings these challenges into sharp focus, offering a highly scientific forum where formulation scientists, analytical experts, manufacturing leaders, and regulatory professionals examine how strong drug product science translates into effective CMC strategy. Emphasis is placed on moving beyond empirical trial‑and‑error toward mechanistic, data‑driven decision‑making that supports earlier risk identification and more resilient CMC packages.

Key themes include stability‑informed formulation design, stress testing to understand degradation pathways, identification and control of critical quality attributes, and the role of advanced analytics in supporting comparability and post‑approval changes. Together, these discussions highlight how integrating scientific insight across development stages can strengthen regulatory readiness and enable more confident progression from early development through commercialization.